What is Obatala Sciences?
Obatala Sciences specializes in creating advanced human-derived hydrogels, stem cells, and functional Fat-on-a-chip models designed to provide deeper insights into metabolic diseases. Their innovative technology is crucial for pre-clinical drug development, enabling a more efficient pathway from research and development to clinical trials. The company's product portfolio includes various ObaCell kits, hydrogels, and specialized media, complemented by expert services in stem cells and biomaterials. Obatala Sciences is committed to developing equitable and effective therapies by enhancing preclinical insights.
How much funding has Obatala Sciences raised?
Obatala Sciences has raised a total of $3.1M across 2 funding rounds:
Debt
$92K
Series A
$3M
Debt (2021): $92K with participation from PPP
Series A (2022): $3M led by Elevate Capital Fund, Benson Capital Partners, Hackett Robertson Tobe Group, Ochsner Lafayette General Healthcare Innovation Fund, and être Venture Capital
Key Investors in Obatala Sciences
Benson Capital Partners
Benson Capital Partners is an investment banking firm based in New Orleans, Louisiana, specializing in the investment banking sector. They focus on providing financial advisory services and capital solutions to companies.
Hackett Robertson Tobe Group
Hackett Robertson Tobe Group is an independent institutional investment consulting firm and registered Investment Adviser that provides customized investment counsel and consulting services, with a focus on public funds and retirement plan sponsors. They are a woman and minority-owned firm.
Ochsner Lafayette General Healthcare Innovation Fund
Ochsner Lafayette General Healthcare Innovation Fund is an investment entity focused on advancing healthcare technologies and solutions. Their participation suggests a strategic interest in innovative medical and life sciences companies.
What's next for Obatala Sciences?
With its recent major strategic investment and a total funding amount of $3.1M, Obatala Sciences is poised to expand its capabilities in life sciences manufacturing. The company's focus on human-derived hydrogels and stem cell technologies for pre-clinical drug development suggests a strategic push towards enhancing the accuracy and efficiency of drug testing. This capital infusion will likely fuel further research and development, potentially leading to new product lines or expanded service offerings aimed at accelerating the discovery of novel therapies for metabolic and other diseases. The company's trajectory indicates a strong commitment to bridging the gap between laboratory research and patient-ready treatments.
See full Obatala Sciences company page
